What is Zacks Research’s Forecast for ResMed Q2 Earnings?

ResMed Inc. (NYSE:RMD) – Zacks Research lifted their Q2 2025 earnings per share (EPS) estimates for ResMed in a research note issued to investors on Thursday, December 5th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings of $2.25 per share for the quarter, up from their previous estimate of $2.24. The consensus estimate for ResMed’s current full-year earnings is $9.28 per share. Zacks Research also issued estimates for ResMed’s Q3 2025 earnings at $2.28 EPS, Q4 2025 earnings at $2.35 EPS, FY2025 earnings at $9.08 EPS, Q2 2026 earnings at $2.33 EPS, Q3 2026 earnings at $2.48 EPS, FY2026 earnings at $9.54 EPS, Q1 2027 earnings at $2.45 EPS and FY2027 earnings at $10.48 EPS.

A number of other analysts have also commented on RMD. Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a research report on Friday, October 25th. StockNews.com upgraded ResMed from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Royal Bank of Canada increased their target price on ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a report on Friday, October 25th. Wolfe Research restated an “underperform” rating and set a $180.00 price target on shares of ResMed in a research note on Wednesday, September 18th. Finally, Baird R W upgraded shares of ResMed to a “strong-buy” rating in a report on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $225.70.

ResMed Price Performance

Shares of NYSE RMD opened at $241.41 on Monday. The firm has a market capitalization of $35.44 billion, a P/E ratio of 31.97, a P/E/G ratio of 1.79 and a beta of 0.68. The firm’s 50-day moving average price is $242.30 and its 200-day moving average price is $226.57. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13. ResMed has a 1-year low of $162.05 and a 1-year high of $260.49.

ResMed (NYSE:RMD) last issued its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same period in the prior year, the firm earned $1.64 earnings per share. ResMed’s revenue was up 11.1% on a year-over-year basis.

ResMed Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Thursday, November 7th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date is Thursday, November 7th. ResMed’s dividend payout ratio is currently 28.08%.

Insider Transactions at ResMed

In other news, CFO Brett Sandercock sold 1,000 shares of the stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $233.47, for a total transaction of $233,470.00. Following the completion of the transaction, the chief financial officer now owns 95,812 shares in the company, valued at approximately $22,369,227.64. This represents a 1.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Justin Leong sold 6,160 shares of ResMed stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $243.09, for a total value of $1,497,434.40. Following the completion of the sale, the insider now directly owns 21,718 shares of the company’s stock, valued at approximately $5,279,428.62. This trade represents a 22.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 52,725 shares of company stock worth $12,516,248 in the last quarter. Insiders own 0.71% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of RMD. True Wealth Design LLC grew its position in shares of ResMed by 2,200.0% in the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 110 shares in the last quarter. Ashton Thomas Securities LLC purchased a new position in ResMed during the 3rd quarter valued at about $34,000. OFI Invest Asset Management purchased a new stake in shares of ResMed in the second quarter worth about $32,000. Financial Connections Group Inc. purchased a new stake in shares of ResMed in the second quarter worth about $37,000. Finally, Blue Trust Inc. boosted its position in shares of ResMed by 182.7% in the second quarter. Blue Trust Inc. now owns 212 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 137 shares during the period. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.